These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 6762360)

  • 1. Renal hypophosphatemic rickets - a review.
    Chan JC
    Int J Pediatr Nephrol; 1982 Dec; 3(4):305-10. PubMed ID: 6762360
    [No Abstract]   [Full Text] [Related]  

  • 2. Medical management of simple familial rickets.
    Fellers FX; Herrera C
    Orthop Clin North Am; 1972 Mar; 3(1):241-9. PubMed ID: 4335061
    [No Abstract]   [Full Text] [Related]  

  • 3. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.
    Harrell RM; Lyles KW; Harrelson JM; Friedman NE; Drezner MK
    J Clin Invest; 1985 Jun; 75(6):1858-68. PubMed ID: 3839245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal hypophosphatemic rickets: growth acceleration after long-term treatment with 1,25-dihydroxyvitamin-D3.
    Chan JC; Lovinger RD; Mamunes P
    Pediatrics; 1980 Sep; 66(3):445-54. PubMed ID: 6893489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of hydrochlorothiazide and amiloride in renal hypophosphatemic rickets.
    Alon U; Chan JC
    Pediatrics; 1985 Apr; 75(4):754-63. PubMed ID: 3885156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone therapy in hypophosphatemic rickets.
    Wilson DM; Lee PD; Morris AH; Reiter EO; Gertner JM; Marcus R; Quarmby VE; Rosenfeld RG
    Am J Dis Child; 1991 Oct; 145(10):1165-70. PubMed ID: 1928011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased growth after long-term oral 1alpha,25-vitamin D3 in childhood renal osteodystrophy.
    Chesney RW; Moorthy AV; Eisman JA; Jax DK; Mazess RB; DeLuca HF
    N Engl J Med; 1978 Feb; 298(5):238-42. PubMed ID: 201843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term influence of calcitriol (1,25-dihydroxyvitamin D) and supplemental phosphate in X-linked hypophosphatemic rickets.
    Chesney RW; Mazess RB; Rose P; Hamstra AJ; DeLuca HF; Breed AL
    Pediatrics; 1983 Apr; 71(4):559-67. PubMed ID: 6300745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of prolonged treatment with 25-hydroxycholecalciferol in hypophosphatemic (vitamin D refractory) rickets and osteomalacia.
    Cohanim M; DeLuca HF; Yendt ER
    Johns Hopkins Med J; 1972 Aug; 131(2):118-32. PubMed ID: 4340527
    [No Abstract]   [Full Text] [Related]  

  • 10. Marked improvement in parameters of renal osteodystrophy with the use of intraperitoneal calcitriol.
    Arora N; Sandroni S; Moles K
    Adv Perit Dial; 1992; 8():62-4. PubMed ID: 1361854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum parathyroid hormone in hypophosphatemic vitamin D-resistant rickets.
    Lewy JE; Cabana EC; Repetto HA; Canterbury JM; Reiss E
    J Pediatr; 1972 Aug; 81(2):294-300. PubMed ID: 4339535
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of long-term oral 1,25-dihydroxyvitamin D in childhood renal osteodystrophy.
    Chesney RW; Hamstra A; Jax DK; Mazess RB; DeLuca HF
    Contrib Nephrol; 1980; 18():55-71. PubMed ID: 7353380
    [No Abstract]   [Full Text] [Related]  

  • 13. Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia.
    Carpenter TO; Mitnick MA; Ellison A; Smith C; Insogna KL
    J Clin Endocrinol Metab; 1994 Jun; 78(6):1378-83. PubMed ID: 8200940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal hypophosphatemic rickets. Growth and mineral metabolism after treatment with calcitriol (1,25-dihydroxyvitamin D3) and phosphate supplementation.
    Tsuru N; Chan JC; Chinchilli VM
    Am J Dis Child; 1987 Jan; 141(1):108-10. PubMed ID: 3788870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth and bone mineral density in a child with X-linked hypophosphatemic rickets: early response to treatment.
    Sugiyama T; Tanaka H; Kawai S
    J Bone Miner Metab; 1999; 17(2):137-40. PubMed ID: 10340642
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hypophosphatemic vitamin D resistant rickets].
    Kinuta K; Seino Y
    Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):593-6. PubMed ID: 9645143
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density.
    Saggese G; Baroncelli GI; Bertelloni S; Perri G
    J Pediatr; 1995 Sep; 127(3):395-402. PubMed ID: 7658269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone.
    Coen G; Taccone Gallucci M; Bonucci E; Ballanti P; Bianchi AR; Bianchini G; Matteucci MC; Mazzaferro S; Picca S; Taggi F; Cinotti GA; Casciani CU
    Miner Electrolyte Metab; 1983; 9(1):19-27. PubMed ID: 6687749
    [No Abstract]   [Full Text] [Related]  

  • 19. Nature of defect responsible for familial vitamin D-resistant rickets (VDRR) based on radioimmunoassay for parathyroid hormone (PTH).
    Roof BS; Piel CF; Gordan GS
    Trans Assoc Am Physicians; 1972; 85():172-80. PubMed ID: 4349621
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of 1,25-dihydroxyvitamin-D3 on renal function, mineral balance, and growth in children with severe chronic renal failure.
    Chan JC; Kodroff MB; Landwehr DM
    Pediatrics; 1981 Oct; 68(4):559-71. PubMed ID: 6895662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.